We are live on ! Find out more

Micro Cap Biotechnology
Stocks Ranked by
Market Capitalization

Name Market cap Price Price
change %
CUE icon
1
Cue Biopharma
CUE
$248M
$248M $34.17 8%
FHTX icon
2
Foghorn Therapeutics
FHTX
$248M
$248M $4.17 1.21%
ALXO icon
3
ALX Oncology
ALXO
$243M
$243M $1.76 6.88%
CAMP icon
4
CAMP4 Therapeutics
CAMP
$242M
$242M $3.86 7.88%
RNAC icon
5
Cartesian Therapeutics
RNAC
$239M
$239M $7.91 0.25%
IVVD icon
6
Invivyd
IVVD
$237M
$237M $0.8053 2.98%
WHWK
7
Whitehawk Therapeutics
WHWK
$230M
$230M $4.04 1.22%
GLSI icon
8
Greenwich LifeSciences
GLSI
$229M
$229M $15.63 2.86%
NGEN
9
NervGen Pharma
NGEN
$229M
$229M $2.13 0.47%
CGEN icon
10
Compugen
CGEN
$228M
$228M $2.41 0%
IPHA
11
Innate Pharma
IPHA
$225M
$225M $2.01 8.06%
AVXL icon
12
Anavex Life Sciences
AVXL
$219M
$219M $2.36 3.28%
ELDN icon
13
Eledon Pharmaceuticals
ELDN
$217M
$217M $2.67 1.48%
ALEC icon
14
Alector
ALEC
$215M
$215M $1.93 5.39%
TARA icon
15
Protara Therapeutics
TARA
$214M
$214M $3.62 3.47%
VRXA
16
Veraxa Biotech AG
VRXA
$214M
$214M $1.51 0.66%
KROS icon
17
Keros Therapeutics
KROS
$213M
$213M $10.74 3.85%
ADAG
18
Adagene
ADAG
$213M
$213M $3.17 6.73%
SLGL icon
19
Sol-Gel Technologies
SLGL
$208M
$208M $63.44 1.49%
NKTX icon
20
Nkarta
NKTX
$206M
$206M $2.87 0.35%
KRRO icon
21
Korro Bio
KRRO
$204M
$204M $13.83 1.71%
TNXP icon
22
Tonix Pharmaceuticals
TNXP
$202M
$202M $11.76 1.2%
ANTX icon
23
AN2 Therapeutics
ANTX
$202M
$202M $5.34 0.37%
PEPG icon
24
PepGen
PEPG
$201M
$201M $2.90 0.35%
SRZN icon
25
Surrozen
SRZN
$199M
$199M $16.93 4.73%
1
2 3 4 5

Micro Cap Biotechnology Stocks at a Glance

Biotechnology companies research and develop novel drugs and therapies, often with no products yet on the market. Clinical-trial readouts and regulatory decisions drive binary stock moves, making pipeline breadth, cash runway, and partnership deals the key variables.

There are 274 micro cap Biotechnology stocks — companies in the Biotechnology industry with a market cap under $250M — worth a combined $18.5B.

The largest by market cap are Cue Biopharma (CUE) at $248M, Foghorn Therapeutics (FHTX) at $248M and ALX Oncology (ALXO) at $243M.

Among institutional investors, Eledon Pharmaceuticals (ELDN) drew the most net new fund positions in Q2 2026: 51 funds opened new positions, taking total fund holders up 40 (33%) quarter-over-quarter.

Market caps and prices updated daily; fund activity based on aggregated SEC 13F filings for Q2 2026.